{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:11Z","timestamp":1786979891976,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023B1515020113"],"award-info":[{"award-number":["2023B1515020113"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["RCYX20221008092935096"],"award-info":[{"award-number":["RCYX20221008092935096"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171197"],"award-info":[{"award-number":["82171197"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lingang Laboratory","award":["LG-GG-202401-ADA070600"],"award-info":[{"award-number":["LG-GG-202401-ADA070600"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00259-024-06835-2","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:01:50Z","timestamp":1720396910000},"page":"3990-4000","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["[18F]-D3FSP \u03b2-amyloid PET imaging in older adults and alzheimer\u2019s disease"],"prefix":"10.1007","volume":"51","author":[{"given":"Anqi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingkai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hank","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2982-0865","authenticated-orcid":false,"given":"Tengfei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"6835_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1159\/000116984","volume":"33","author":"H Braak","year":"1993","unstructured":"Braak H, Braak E, Bohl J. Staging of alzheimer-related cortical destruction. Eur Neurol. 1993;33:403\u20138.","journal-title":"Eur Neurol"},{"key":"6835_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275\u201383.","journal-title":"JAMA"},{"key":"6835_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2967\/jnumed.116.176115","volume":"58","author":"T Guo","year":"2017","unstructured":"Guo T, Brendel M, Grimmer T, Rominger A, Yakushev I. Predicting Regional Pattern of Longitudinal \u03b2-Amyloid Accumulation by Baseline PET. J Nucl Med. 2017;58:639\u201345.","journal-title":"J Nucl Med"},{"key":"6835_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","volume":"77","author":"AS Fleisher","year":"2020","unstructured":"Fleisher AS, Pontecorvo MJ, Devous MD, Lu M, Arora AK, Truocchio SP, et al. Positron Emission Tomography Imaging with [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. JAMA Neurol. 2020;77:829.","journal-title":"JAMA Neurol"},{"key":"6835_CR5","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.biopsych.2020.06.029","volume":"89","author":"T Guo","year":"2021","unstructured":"Guo T, Korman D, Baker SL, Landau SM, Jagust WJ. Longitudinal cognitive and biomarker measurements support a unidirectional pathway in Alzheimer\u2019s Disease Pathophysiology. Biol Psychiatry. 2021;89:786\u201394.","journal-title":"Biol Psychiatry"},{"key":"6835_CR6","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1001\/jama.2019.7437","volume":"321","author":"CR Jack","year":"2019","unstructured":"Jack CR, Wiste HJ, Therneau TM, Weigand SD, Knopman DS, Mielke MM, et al. Associations of amyloid, Tau, and Neurodegeneration Biomarker profiles with Rates of memory decline among individuals without dementia. JAMA. 2019;321:2316.","journal-title":"JAMA"},{"key":"6835_CR7","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","volume":"389","author":"RA Sperling","year":"2023","unstructured":"Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, et al. Trial of Solanezumab in Preclinical Alzheimer\u2019s Disease. N Engl J Med. 2023;389:1096\u2013107.","journal-title":"N Engl J Med"},{"key":"6835_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"6835_CR9","doi-asserted-by":"publisher","unstructured":"Yao X, Zha Z, Zhao R, Choi SR, Ploessl K, Liu F et al. Optimization of solid-phase extraction (SPE)in the preparation of [18F]D3FSP: A new PET imaging agent for mapping A\u03b2 plaques. Nucl Med Biol [Internet]. Elsevier Inc.; 2019;71:54\u201364. https:\/\/doi.org\/10.1016\/j.nucmedbio.2019.05.002.","DOI":"10.1016\/j.nucmedbio.2019.05.002"},{"key":"6835_CR10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2967\/jnumed.114.148981","volume":"56","author":"SM Landau","year":"2015","unstructured":"Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K, et al. Measurement of longitudinal \u03b2-Amyloid change with 18 F-Florbetapir PET and standardized Uptake Value Ratios. J Nucl Med. 2015;56:567\u201374.","journal-title":"J Nucl Med"},{"key":"6835_CR11","doi-asserted-by":"crossref","unstructured":"Villemagne VL, Bourgeat P, Dor\u00e9 V, Macaulay L, Williams R, Ames D et al. IC-P\u2010016: amyloid imaging in therapeutic trials: the quest for the optimal reference region. Alzheimer\u2019s Dement. 2015;11.","DOI":"10.1016\/j.jalz.2015.06.036"},{"key":"6835_CR12","doi-asserted-by":"crossref","unstructured":"Heeman F, Hendriks J, Alves IL, Ossenkoppele R, Tolboom N, van Berckel BNM, et al. [11\u00a0C]PIB amyloid quantification: effect of reference region selection. EJNMMI Res. Springer Science and Business Media Deutschland GmbH; 2020. p. 10.","DOI":"10.1186\/s13550-020-00714-1"},{"key":"6835_CR13","first-page":"193","volume":"56","author":"C Rowe","year":"2015","unstructured":"Rowe C, Dor\u00e9 V, Bourgeat P, Thurfjell L, Macaulay S, Williams R, et al. Longitudinal assessment of A\u03b2 accumulation in non-demented individuals: a 18F-flutemetamol study. J Nucl Med Soc Nuclear Med. 2015;56:193.","journal-title":"J Nucl Med Soc Nuclear Med"},{"key":"6835_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.nucmedbio.2020.03.003","volume":"92","author":"Z Zha","year":"2021","unstructured":"Zha Z, Ploessl K, Choi SR, Alexoff D, Kung HF. Preclinical evaluation of [18F]D3FSP, deuterated AV-45, for imaging of \u03b2-amyloid in the brain. Nucl Med Biol. 2021;92:97\u2013106.","journal-title":"Nucl Med Biol"},{"key":"6835_CR15","first-page":"1457","volume":"60","author":"D Wong","year":"2019","unstructured":"Wong D, Kuwabara H, Kitzmiller K, Nandi A, Brinson Z, George N, et al. Comparison of [ 18F]D3FSP([18F]P16-129) and [18F] AV45 in Alzheimers Disease. J Nucl Med Soc Nuclear Med. 2019;60:1457.","journal-title":"J Nucl Med Soc Nuclear Med"},{"key":"6835_CR16","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/alz.12697","volume":"19","author":"S Zicha","year":"2023","unstructured":"Zicha S, Bateman RJ, Shaw LM, Zetterberg H, Bannon AW, Horton WA, et al. Comparative analytical performance of multiple plasma A\u03b242 and A\u03b240 assays and their ability to predict positron emission tomography amyloid positivity. Alzheimer\u2019s Dement. 2023;19:956\u201366.","journal-title":"Alzheimer\u2019s Dement"},{"key":"6835_CR17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422\u201333.","journal-title":"Lancet Neurol"},{"key":"6835_CR18","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE, et al. Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease. Brain. 2021;144:3505\u201316.","journal-title":"Brain"},{"key":"6835_CR19","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1093\/brain\/awaa342","volume":"143","author":"AL Benedet","year":"2020","unstructured":"Benedet AL, Leuzy A, Pascoal TA, Ashton NJ, Mathotaarachchi S, Savard M, et al. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer\u2019s disease. Brain. 2020;143:3793\u2013804.","journal-title":"Brain"},{"key":"6835_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/alz.12248","volume":"17","author":"E Guzm\u00e1n-V\u00e9lez","year":"2021","unstructured":"Guzm\u00e1n-V\u00e9lez E, Zetterberg H, Fox\u2010Fuller JT, Vila\u2010Castelar C, Sanchez JS, Baena A, et al. Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non\u2010demented individuals with autosomal\u2010dominant Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2021;17:813\u201321.","journal-title":"Alzheimer\u2019s Dement"},{"key":"6835_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13195-020-00665-8","volume":"12","author":"T Guo","year":"2020","unstructured":"Guo T, Korman D, La Joie R, Shaw LM, Trojanowski JQ, Jagust WJ, et al. Normalization of CSF pTau measurement by A\u03b240 improves its performance as a biomarker of Alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12:97.","journal-title":"Alzheimers Res Ther"},{"key":"6835_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1001\/jamaneurol.2015.3098","volume":"73","author":"RC Petersen","year":"2016","unstructured":"Petersen RC, Wiste HJ, Weigand SD, Rocca WA, Roberts RO, Mielke MM, et al. Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol. 2016;73:85\u201392.","journal-title":"JAMA Neurol"},{"key":"6835_CR23","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of Amyloid Positron Emission Tomography with subsequent change in Clinical Management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321:1286.","journal-title":"JAMA"},{"key":"6835_CR24","doi-asserted-by":"publisher","first-page":"e1512","DOI":"10.1212\/WNL.0000000000009216","volume":"94","author":"T Guo","year":"2020","unstructured":"Guo T, Landau SM, Jagust WJ. Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults. Neurology. 2020;94:e1512\u201324.","journal-title":"Neurology"},{"key":"6835_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13195-024-01458-z","volume":"16","author":"Z Liu","year":"2024","unstructured":"Liu Z, Shi D, Cai Y, Li A, Lan G, Sun P, et al. Pathophysiology characterization of Alzheimer\u2019s disease in South China\u2019s aging population: for the Greater-Bay-Area healthy aging brain study (GHABS). Alzheimers Res Ther. 2024;16:84.","journal-title":"Alzheimers Res Ther"},{"key":"6835_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","volume":"74","author":"RC Petersen","year":"2010","unstructured":"Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74:201\u20139.","journal-title":"Neurology"},{"key":"6835_CR27","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Ch\u00e9telat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2014;10:844\u201352.","journal-title":"Alzheimer\u2019s Dement"},{"key":"6835_CR28","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.neuroimage.2006.01.021","volume":"31","author":"RS Desikan","year":"2006","unstructured":"Desikan RS, S\u00e9gonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. NeuroImage. 2006;31:968\u201380.","journal-title":"NeuroImage"},{"key":"6835_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack","year":"2017","unstructured":"Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2017;13:205\u201316.","journal-title":"Alzheimer\u2019s Dement"},{"key":"6835_CR30","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.neuroimage.2017.05.058","volume":"157","author":"A Maass","year":"2017","unstructured":"Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer\u2019s disease. NeuroImage. 2017;157:448\u201363.","journal-title":"NeuroImage"},{"key":"6835_CR31","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"6835_CR32","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1111\/jgs.13820","volume":"63","author":"P Julayanont","year":"2015","unstructured":"Julayanont P, Tangwongchai S, Hemrungrojn S, Tunvirachaisakul C, Phanthumchinda K, Hongsawat J, et al. The Montreal Cognitive Assessment - Basic: a Screening Tool for mild cognitive impairment in illiterate and low-educated Elderly adults. J Am Geriatr Soc. 2015;63:2550\u20134.","journal-title":"J Am Geriatr Soc"},{"key":"6835_CR33","doi-asserted-by":"crossref","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. Academic; 2013.","DOI":"10.4324\/9780203771587"},{"key":"6835_CR34","first-page":"1","volume":"8","author":"S Shokouhi","year":"2016","unstructured":"Shokouhi S, McKay JW, Baker SL, Kang H, Brill AB, Gwirtsman HE, et al. Reference tissue normalization in longitudinal 18F-florbetapir positron emission tomography of late mild cognitive impairment. Alzheimer\u2019s Res Ther Alzheimer\u2019s Res Therapy. 2016;8:1\u201312.","journal-title":"Alzheimer\u2019s Res Ther Alzheimer\u2019s Res Therapy"},{"key":"6835_CR35","doi-asserted-by":"crossref","unstructured":"Cho SH, Choe YS, Park S, Kim YJ, Kim HJ, Jang H et al. Appropriate reference region selection of 18F-florbetaben and 18F-flutemetamol beta-amyloid PET expressed in Centiloid. Sci Rep Nat Res; 2020;10.","DOI":"10.1038\/s41598-020-70978-z"},{"key":"6835_CR36","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.2967\/jnumed.116.187351","volume":"58","author":"S Bullich","year":"2017","unstructured":"Bullich S, Villemagne VL, Catafau AM, Jovalekic A, Koglin N, Rowe CC, et al. Optimal reference region to measure longituDinal amyloid-b change with 18F-Florbetaben PET. J Nucl Med. 2017;58:1300\u20136.","journal-title":"J Nucl Med"},{"key":"6835_CR37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00259-011-2021-8","volume":"39","author":"V Camus","year":"2012","unstructured":"Camus V, Payoux P, Barr\u00e9 L, Desgranges B, Voisin T, Tauber C, et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging. 2012;39:621\u201331.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6835_CR38","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.jalz.2012.10.007","volume":"9","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer\u2019s disease dementia, mild cognitive impairment, and normal aging. Alzheimer\u2019s Dement. 2013;9:S72\u201383.","journal-title":"Alzheimer\u2019s Dement"},{"key":"6835_CR39","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","volume":"10","author":"H Barthel","year":"2011","unstructured":"Barthel H, Gertz H-J, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-\u03b2 PET with florbetaben (18F) in patients with Alzheimer\u2019s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424\u201335.","journal-title":"Lancet Neurol"},{"key":"6835_CR40","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jalz.2012.01.006","volume":"9","author":"R Duara","year":"2013","unstructured":"Duara R, Loewenstein DA, Shen Q, Barker W, Potter E, Varon D, et al. Amyloid positron emission tomography with 18 F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer\u2019s disease. Alzheimer\u2019s Dement Elsevier Ltd. 2013;9:295\u2013301.","journal-title":"Alzheimer\u2019s Dement Elsevier Ltd"},{"key":"6835_CR41","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimer\u2019s Dement. 2018;14:989\u201397.","journal-title":"Alzheimer\u2019s Dement"},{"key":"6835_CR42","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med. 2020;26:387\u201397.","journal-title":"Nat Med"},{"key":"6835_CR43","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/alz.12724","volume":"19","author":"P Chatterjee","year":"2023","unstructured":"Chatterjee P, Pedrini S, Doecke JD, Thota R, Villemagne VL, Dor\u00e9 V, et al. Plasma A\u03b242\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer\u2019s disease continuum: a cross-sectional and longitudinal study in the AIBL cohort. Alzheimer\u2019s Dement. 2023;19:1117\u201334.","journal-title":"Alzheimer\u2019s Dement"},{"key":"6835_CR44","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13195-020-00682-7","volume":"12","author":"IMW Verberk","year":"2020","unstructured":"Verberk IMW, Thijssen E, Koelewijn J, Mauroo K, Vanbrabant J, de Wilde A, et al. Combination of plasma amyloid beta(1\u201342\/1\u201340) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res Ther. 2020;12:118.","journal-title":"Alzheimers Res Ther"},{"key":"6835_CR45","doi-asserted-by":"publisher","first-page":"46563","DOI":"10.1002\/alz.046563","volume":"16","author":"M Sathishkumar","year":"2020","unstructured":"Sathishkumar M, Larson MS, Taylor L, Keator D, Hollearn MK, Miranda BA, et al. Hippocampal volume loss is associated with PET amyloid deposition in nondemented elderly individuals. Alzheimer\u2019s Dement. 2020;16:46563.","journal-title":"Alzheimer\u2019s Dement"},{"key":"6835_CR46","unstructured":"Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA et al. Use of Florbetapir-PET for Imaging-Amyloid Pathology."},{"key":"6835_CR47","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00259-013-2620-7","volume":"41","author":"H Ito","year":"2014","unstructured":"Ito H, Shinotoh H, Shimada H, Miyoshi M, Yanai K, Okamura N, et al. Imaging of amyloid deposition in human brain using positron emission tomography and [18F]FACT: comparison with [11\u00a0C]PIB. Eur J Nucl Med Mol Imaging. 2014;41:745\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6835_CR48","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3 study. Alzheimer\u2019s Dement. 2015;11:964\u201374.","journal-title":"Alzheimer\u2019s Dement"},{"key":"6835_CR49","doi-asserted-by":"publisher","first-page":"880","DOI":"10.2967\/jnumed.112.114785","volume":"54","author":"CC Rowe","year":"2013","unstructured":"Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, et al. Head-to-head comparison of11C-PiB and18F-AZD4694 (NAV4694) for \u03b2-amyloid imaging in aging and dementia. J Nucl Med. 2013;54:880\u20136.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06835-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06835-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06835-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T05:19:09Z","timestamp":1730351949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06835-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":49,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["6835"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06835-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"6 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were under the ethical standards of the institutional and\/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}